deltatrials
Terminated PHASE1 NCT00004261

EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma

A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas

Sponsor: National Cancer Institute (NCI)

Conditions Breast Cancer Cervical Cancer Head and Neck Cancer Prostate Cancer Sarcoma
Interventions EF5 biopsy flow cytometry fluorescent antibody technique immunohistochemistry staining method
Updated 6 times since 2017 Last updated: Feb 20, 2018 Started: Dec 31, 1999 Primary completion: Jun 30, 2002

A PHASE1 clinical study on Breast Cancer and Cervical Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Mar 2018 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Mar 2018 [monthly]

    Terminated PHASE1

    First recorded

Dec 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • University Health Network, Toronto
Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Toronto, Canada